Edition:
United Kingdom

Co-Diagnostics Inc (CODX.OQ)

CODX.OQ on NASDAQ Stock Exchange Capital Market

2.35USD
2:35pm GMT
Change (% chg)

$0.10 (+4.44%)
Prev Close
$2.25
Open
$2.31
Day's High
$2.35
Day's Low
$2.31
Volume
1,541
Avg. Vol
7,293
52-wk High
$6.66
52-wk Low
$1.45

Latest Key Developments (Source: Significant Developments)

Co-Diagnostics Inc And LGC, Biosearch Technologies Sign License Agreement For Coprimer Technology
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Co-Diagnostics Inc ::CO-DIAGNOSTICS, INC. AND LGC, BIOSEARCH TECHNOLOGIES SIGN LICENSE AGREEMENT FOR COPRIMER TECHNOLOGY.CO-DIAGNOSTICS INC - CO-DIAGNOSTICS AGREES TO LICENSE COPRIMERS FOR USE IN AGRICULTURAL APPLICATIONS.  Full Article

Co-Diagnostics Receives CE Mark For Zika Screening Test
Thursday, 18 Oct 2018 

Oct 18 (Reuters) - Co-Diagnostics Inc ::CO-DIAGNOSTICS, INC. RECEIVES CE MARK FOR ZIKA SCREENING TEST.CO-DIAGNOSTICS INC - CO'S LOGIX SMART ZIKA TEST TO BE AVAILABLE FOR PURCHASE WITH CE MARK.  Full Article

Co-Diagnostics Receives CE Mark For Tuberculosis Test Kit
Wednesday, 25 Jul 2018 

July 25 (Reuters) - Co-Diagnostics Inc ::CO-DIAGNOSTICS RECEIVES CE MARK FOR TUBERCULOSIS TEST KIT.  Full Article

Co-Diagnostics Completes Submission Of CE Mark Registration For Tuberculosis Screening Test
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Co-Diagnostics Inc ::CO-DIAGNOSTICS COMPLETES SUBMISSION OF CE MARK REGISTRATION FOR TUBERCULOSIS SCREENING TEST.CO-DIAGNOSTICS INC - COMPANY'S LOGIX SMART MTB TEST TO BE AVAILABLE FOR PURCHASE WITH CE MARK IN AUGUST 2018.  Full Article

Co-Diagnostics, Inc. Announces Advancement Of Co-Primers™ Technology In Multiplex SNP Genotyping
Tuesday, 5 Jun 2018 

Co-Diagnostics Inc ::CO-DIAGNOSTICS, INC. ANNOUNCES ADVANCEMENT OF CO-PRIMERS™ TECHNOLOGY IN MULTIPLEX SNP GENOTYPING.CO-DIAGNOSTICS INC - PROOF OF CONCEPT STUDY SUCCESSFUL IN DEMONSTRATING POTENTIAL SNP MULTIPLEXING APPLICATIONS.  Full Article

Co-Diagnostics Enters Into Lease For Upgraded Laboratory Facility In Salt Lake City
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Co-Diagnostics Inc ::CO-DIAGNOSTICS - ENTERS INTO LEASE FOR BIOLOGICAL SAFETY LEVEL 2 LABORATORY FACILITY IN SALT LAKE CITY, UTAH.CO-DIAGNOSTICS INC - LABORATORY WILL MEET CGMP REQUIREMENTS OF FDA.  Full Article

Co-Diagnostics Inc says qtrly loss per share $‍0.33​
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Co-Diagnostics Inc -:Co-Diagnostics, Inc. Reports Q3 financial results and updates corporate developments.Co-Diagnostics Inc - qtrly loss per share $‍0.33​.  Full Article

Co-Diagnostics to sign purchase agreement with Medcis Pathlabs
Tuesday, 5 Sep 2017 

Sept 5 (Reuters) - Co-diagnostics Inc ::Co-Diagnostics, Inc to sign purchase agreement with Medcis Pathlabs.Co-Diagnostics- co, Medcis Pathlabs India Pvt. Ltd, have agreed to terms of purchase agreement for co-diagnostics products to be used throughout India.  Full Article

No consensus analysis data available.